Continuing or adding IL-2 in patients treated with antiretroviral therapy (ACTG Protocol A5051, a rollover trial of ACTG Protocol A328).

Bosch, Ronald J; Pollard, Richard B; Landay, Alan; Aga, Evgenia; Fox, Lawrence; Mitsuyasu, Ronald

Bosch, Ronald J; Pollard, Richard B; Landay, Alan; Aga, Evgenia; Fox, Lawrence; Mitsuyasu, Ronald.

Affiliation

Bosch RJ; Harvard School of Public Health, Boston MA, USA. rbosch@hsph.harvard.edu.

AIDS Res Ther ; 7: 30, 2010 Aug 05.

Article in En | MEDLINE | ID: mdl-20687947

Fulltext

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2924251
https://dx.doi.org/10.1186/1742-6405-7-30

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Clinical_trials / Guideline Language: En Journal: AIDS Res Ther Year: 2010 Type: Article Affiliation country: United States

Fulltext

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2924251
https://dx.doi.org/10.1186/1742-6405-7-30

XML

PubMed Links

Search on Google